Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Front Cell Infect Microbiol ; 12: 907043, 2022.
Article in English | MEDLINE | ID: mdl-35873171

ABSTRACT

Trypanosoma cruzi, the causal agent of Chagas disease, has peroxiredoxins (PRXs) expressed in all stages of the parasite and whose function is to detoxify oxidizing agents, such as reactive oxygen species (ROS). These proteins are central for the survival and replication of the parasite and have been proposed as virulence factors. Because of their importance, they have also been considered as possible therapeutic targets, although there is no specific drug against them. One of them, the mitochondrial PRX (TcMPX), is important in the detoxification of ROS in this organelle and has a role in the infectivity of T. cruzi. However, their structural characteristics are unknown, and possible inhibitors have not been proposed. The aim was to describe in detail some structural characteristics of TcMPX and compare it with several PRXs to find possible similarities and repositioning the antibiotic Thiostrepton as a potential inhibitor molecule. It was found that, in addition to the characteristic active site of a 2-cys PRX, this protein has a possible transmembrane motif and motifs involved in resistance to hyper oxidation. The homology model suggests a high structural similarity with human PRX3. This similarity was corroborated by cross-recognition using an anti-human PRX antibody. In addition, molecular docking showed that Thiostrepton, a potent inhibitor of human PRX3, could bind to TcMPX and affect its function. Our results show that Thiostrepton reduces the proliferation of T. cruzi epimastigotes, cell-derived trypomastigotes, and blood trypomastigotes with low cytotoxicity on Vero cells. We also demonstrated a synergic effect of Thriostepton and Beznidazol. The convenience of seeking treatment alternatives against T. cruzi by repositioning compounds as Thiostrepton is discussed.


Subject(s)
Chagas Disease , Trypanosoma cruzi , Animals , Chagas Disease/drug therapy , Chagas Disease/parasitology , Chlorocebus aethiops , Humans , Molecular Docking Simulation , Peroxiredoxin III/metabolism , Peroxiredoxin III/pharmacology , Peroxiredoxin III/therapeutic use , Peroxiredoxins/metabolism , Reactive Oxygen Species/metabolism , Thiostrepton/metabolism , Thiostrepton/pharmacology , Thiostrepton/therapeutic use , Trypanosoma cruzi/metabolism , Vero Cells
2.
Insect Biochem Mol Biol ; 139: 103673, 2021 12.
Article in English | MEDLINE | ID: mdl-34700021

ABSTRACT

Defensins are one of the major families of antimicrobial peptides (AMPs) that are widely distributed in insects. In Triatomines (Hemiptera: Reduviidae) vectors of Trypanosoma cruzi the causative agent of Chagas disease, two large groups of defensin isoforms have been described: type 1 and type 4. The aim of this study was to analyze the trypanocidal activity of a type 1 recombinant defensin (rDef1.3) identified in Triatoma (Meccus) pallidipennis, an endemic specie from México. The trypanocidal activity of this defensin was evaluated in vitro, against the parasites T. cruzi, T. rangeli, and two species of Leishmania (L. mexicana and L. major) both causative agents of cutaneous leishmaniasis. Our data demonstrated that the defensin was active against all the parasites although in different degrees. The defensin altered the morphology, reduced the viability and inhibited the growth of T.cruzi. When tested against T. rangeli (a parasite that infects a variety of mammalian species), stronger morphological effects where observed. Surprisingly the greatest effects were observed against the two Leishmania species, of which L. major was the parasite most affected with 50% of dead cells or with damaged membranes, in addition of a reduction in its proliferative capacity in culture. These results suggest that rDef1.3 has an important antimicrobial effect against trypanosomatids which cause some of the more important neglected tropical diseases transmitted by insect vectors.


Subject(s)
Defensins/genetics , Insect Proteins/genetics , Leishmania/drug effects , Triatoma/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma/drug effects , Amino Acid Sequence , Animals , Defensins/chemistry , Defensins/metabolism , Insect Proteins/chemistry , Insect Proteins/metabolism , Phylogeny , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Alignment , Triatoma/genetics
3.
Biosci Rep ; 38(5)2018 10 31.
Article in English | MEDLINE | ID: mdl-30181380

ABSTRACT

Chagas disease remains a serious health problem for countries where the most common mode of transmission is infection contracted from the feces of a Triatominae insect vector. In México, 32 species of Triatoma have been identified; amongst them, Triatoma (Meccus) pallidipennis is an endemic species reported to have high percentages of infection with T. cruzi Defensins, cysteine-rich cationic peptides, are a family of antimicrobial peptides (AMPs); the synthesis of these molecules is crucial for insect's immune defense. In the present study, the genes encoding defensins in T. pallidipennis were sequenced with the purpose of identifying the variability of these genes in a Mexican vector of T. cruzi We found 12 different genes encoding three mature peptides, all of which had the typical folding of a functional insect defensin. In this work two Defensins type 1 and one type 4 were identified. The pro-peptide domain was highly variable and the mature peptide was not. This is the first report focus on variability of defensins from an epidemiologically important Triatoma in Mexico.


Subject(s)
Chagas Disease/genetics , Defensins/genetics , Peptides/genetics , Triatoma/genetics , Animals , Chagas Disease/epidemiology , Chagas Disease/transmission , Endemic Diseases/prevention & control , Feces , Humans , Insect Vectors/genetics , Mexico/epidemiology , Peptides/chemistry , Protein Folding , Triatoma/pathogenicity
4.
PLoS One ; 10(3): e0120221, 2015.
Article in English | MEDLINE | ID: mdl-25757085

ABSTRACT

The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor involved in neurodegenerative and inflammatory disorders. RAGE induces cellular signaling upon binding to a variety of ligands. Evidence suggests that RAGE up-regulation is involved in quinolinate (QUIN)-induced toxicity. We investigated the QUIN-induced toxic events associated with early noxious responses, which might be linked to signaling cascades leading to cell death. The extent of early cellular damage caused by this receptor in the rat striatum was characterized by image processing methods. To document the direct interaction between QUIN and RAGE, we determined the binding constant (Kb) of RAGE (VC1 domain) with QUIN through a fluorescence assay. We modeled possible binding sites of QUIN to the VC1 domain for both rat and human RAGE. QUIN was found to bind at multiple sites to the VC1 dimer, each leading to particular mechanistic scenarios for the signaling evoked by QUIN binding, some of which directly alter RAGE oligomerization. This work contributes to the understanding of the phenomenon of RAGE-QUIN recognition, leading to the modulation of RAGE function.


Subject(s)
Quinolinic Acid/chemistry , Receptor for Advanced Glycation End Products/chemistry , Animals , Brain/metabolism , Brain/pathology , Male , Molecular Docking Simulation , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , Oxidative Stress , Protein Binding , Quinolinic Acid/physiology , Rats, Wistar , Receptor for Advanced Glycation End Products/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...